Podcasts about tumors

AI isn't just writing your emails anymore—it's reading your hormones and mapping your risk. In this episode, endocrinologist and longevity doctor Dr. Fady Hannah-Shmouni talks about full-body MRIs, cancer blood tests, muscle-driven longevity, HRT, and an at-home cortisol test called ELI. We explore where AI, wearables, and testing truly help women, and where they fuel anxiety, waste money, and dull intuition. We also get real about supplements, bad actors in wellness, and what actually matters if you want to stay strong and functional at 80+. Listen if you want a grounded roadmap for using data, testing, and hormone support to extend your healthspan—not just add more noise to your wellness life. WE TALK ABOUT:  06:00 - Why the future of prevention is continuous data, not yearly check-ups 09:15 - From bulky wearables to ingestibles and toilet sensors: where tracking is headed 13:25 - The $10 trillion wellness economy, influencer noise, and why most women feel lost 18:22 - The truth about supplements: Risks, contaminants, and the few "non-negotiables" 22:30 - Why you don't need 20 biohacks to live longer 28:00 - Tumor-cell blood tests, full-body MRI, and how to think about false positives 35:00 - Sick-care vs wellness: Why women are pushed into the wellness economy 38:05 - How ELI works: Instant saliva cortisol, AI, and a new "Fitbit for your stress" 44:15 - CRP, inflammation, and why a low score is a longevity superpower 48:10 - Muscle as a longevity organ and why women can't "Pilates only" forever 52:10 - Perimenopause, andropause, lost productivity, and why this decade is a wake-up call 57:30 - HRT and dementia/heart disease risk: What the newer evidence suggests SPONSORS: Join me in Costa Rica for Optimize Her, a 5-night luxury women's retreat in Costa Rica with yoga, healing rituals, and biohacking workshops—only 12 spots available. Feeling bloated, tired, or hormonally off? Try BiOptimizers — supplements that actually absorb and work for women's health. Get 15% off with code BIOHACKINGBRITTANY. RESOURCES: Free gift: Download my hormone-balancing, fertility-boosting chocolate recipe. Explore my luxury retreats and wellness events for women. Shop my faves: Check out my Amazon storefront for wellness essentials. ELI Health website and Instagram Dr. Fady Hannah-Shmouni's Instagram LET'S CONNECT: Instagram, TikTok, Facebook Shop my favorite health products Listen on Spotify, Apple Podcasts, YouTube Music

BUFFALO, NY – November 18, 2025 – A new #review was #published in Oncotarget (Volume 16) on November 14, 2025, titled “Mechanism of anticancer action of bifidobacterium: Insights from gut microbiota.” This review, led by first author Hoang Do and correspondent author Ashakumary Lakshmikuttyamma from Thomas Jefferson University, explores how bifidobacterium, a common probiotic found in the gut, may contribute to cancer prevention and therapy. By analyzing existing studies, the authors highlight the growing importance of gut health in cancer treatment and shed light on how bifidobacterium could complement standard cancer therapies. Bifidobacterium is widely known for promoting digestive health and is often included in fermented foods and dietary supplements. However, emerging evidence suggests it may also play a broader role in immune regulation and cancer defense. The review explains how certain strains of bifidobacterium may enhance the effectiveness of chemotherapy, radiation, and immunotherapy in cancers such as breast, lung, colorectal, and gastric cancers. According to the review, bifidobacterium influences cancer outcomes through several biological mechanisms. It helps regulate immune function by reducing inflammation and supporting the activity of immune cells that target tumors. For instance, strains like B. longum and B. breve have been shown to lower levels of harmful inflammatory markers and boost anti-inflammatory responses. These changes can make cancer treatments more effective while also reducing side effects. “Presence of Bifidobacterium breve in gut microbiota extended the median progression-free survival of NSCLC patients.” The review also discusses how bifidobacterium helps detoxify the body by breaking down cancer-causing compounds and limiting their ability to damage cells. In preclinical studies, the probiotic reduced the activity of enzymes that produce carcinogens and helped in converting food-based substances into cancer-fighting agents. Some strains were even found to suppress genes that promote tumor growth and increase molecules that trigger cancer cell death. The authors emphasize that diet plays a critical role in supporting the growth of bifidobacterium. Foods rich in dietary fiber, especially those containing inulin and oligosaccharides like garlic, onions, or leeks, can help increase its levels in the gut. This suggests that simple dietary changes could not only improve gut health but also support cancer prevention and treatment strategies. Although the review presents compelling evidence, the authors stress the need for more clinical trials to determine how different strains of bifidobacterium affect specific types of cancer. Personalized approaches may be necessary to match the right probiotic strains with individual treatment plans. As research continues to uncover the link between gut microbes and cancer, bifidobacterium stands out as a promising natural ally that could enhance the body's defenses and improve cancer treatment outcomes. DOI - https://doi.org/10.18632/oncotarget.28779 Correspondence to - Ashakumary Lakshmikuttyamma - axl025@jefferson.edu Abstract video - https://www.youtube.com/watch?v=KTWJDAN15lY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28779 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

As lung cancer treatments become more complex, is a collaborative tumor board more essential than ever? We're kicking off the 2025 NSCLC Creator Weekend™ series with an in-studio panel discussion on the multidisciplinary management of lung cancer. The panel includes experts from medical oncology, thoracic surgery, radiation oncology, and interventional pulmonology from major institutions in Los Angeles. --- This podcast is supported by an educational grant from Johnson & Johnson and Varian. --- SYNPOSIS They discuss the operation of tumor boards at their respective institutions, the impact of virtual meetings, optimal strategies for mediastinal staging, the management of early-stage lung cancer, and the emerging role of ablation therapy. The conversation dives into the complexities of treating patients with recurrence or metastatic disease, highlighting the importance of collaborative decision-making in navigating these challenging scenarios. The episode emphasizes the critical role of multidisciplinary tumor boards in providing informed, patient-centered care. --- TIMESTAMPS 00:00 - Introduction06:59 - Role of Pulmonologists in Tumor Boards12:08 - Importance of Tissue Diagnosis24:52 - Lung Cancer Screening and Stigma34:01 - Interventional Radiology and Biopsies46:21 - Challenges with Immunotherapy and Radiation53:44 - The Importance of Multidisciplinary Teams54:24 - Final Thoughts --- RESOURCES American Lung Association 2024 Datahttps://www.lung.org/getmedia/12020193-7fb3-46b8-8d78-0e5d9cd8f93c/SOLC-2024.pdf National Lung Screening Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1102873 Checkmate 816https://www.nejm.org/doi/full/10.1056/NEJMoa2202170 PACIFIC Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1709937

Dr. Jay Lalezari, CEO of CytoDyn, is focused on solid tumor immunology, particularly in triple-negative breast cancer, where their lead drug, leronlimab, is showing significant long-term survival benefits.  This monoclonal antibody targets the CCR5 receptor, converting cold tumors into hot tumors and making them more susceptible to immunotherapy checkpoint inhibitors. Work with leronlimab for 20 years has demonstrated the potential for use in colorectal cancer as well as TNBC, and to vastly expand the patient population that could benefit from immunotherapy. Jay explains, "When I became CEO back in November of 2023, my first order of business was to figure out where CytoDyn should go with this intriguing monoclonal antibody called leronlimab that targets CCR5. And we looked at a number of indications, and by far and away, the data that we found in solid tumor oncology is clearly the place CytoDyn will go to create the most benefit for patients and the most benefit for our shareholders. We recently presented some data in triple-negative breast cancer that is truly remarkable and potentially paradigm-shifting in the world of solid tumor oncology."   "Over the years, it became clear that CCR5 was not just for the virus to get inside the cell, but was playing a key role in setting up the tumor microenvironment in a variety of solid tumors that were CCR5 positive. That included typically triple-negative breast cancer, colon cancer, prostate cancer, pancreatic cancer, sarcoma, glioblastoma, and the urothelial cancers in particular. So CCR5 helps the cancer set up a tumor microenvironment that helps it both build blood vessels to provide nourishment for the cancer and attract suppressor cells that keep the host immune system at bay."  #CytoDyn #Oncology #Leronlimab #TNBC #ColorectalCancer #CCR5 cytodyn.com Download the transcript here

Dr. Jay Lalezari, CEO of CytoDyn, is focused on solid tumor immunology, particularly in triple-negative breast cancer, where their lead drug, leronlimab, is showing significant long-term survival benefits.  This monoclonal antibody targets the CCR5 receptor, converting cold tumors into hot tumors and making them more susceptible to immunotherapy checkpoint inhibitors. Work with leronlimab for 20 years has demonstrated the potential for use in colorectal cancer as well as TNBC, and to vastly expand the patient population that could benefit from immunotherapy. Jay explains, "When I became CEO back in November of 2023, my first order of business was to figure out where CytoDyn should go with this intriguing monoclonal antibody called leronlimab that targets CCR5. And we looked at a number of indications, and by far and away, the data that we found in solid tumor oncology is clearly the place CytoDyn will go to create the most benefit for patients and the most benefit for our shareholders. We recently presented some data in triple-negative breast cancer that is truly remarkable and potentially paradigm-shifting in the world of solid tumor oncology."   "Over the years, it became clear that CCR5 was not just for the virus to get inside the cell, but was playing a key role in setting up the tumor microenvironment in a variety of solid tumors that were CCR5 positive. That included typically triple-negative breast cancer, colon cancer, prostate cancer, pancreatic cancer, sarcoma, glioblastoma, and the urothelial cancers in particular. So CCR5 helps the cancer set up a tumor microenvironment that helps it both build blood vessels to provide nourishment for the cancer and attract suppressor cells that keep the host immune system at bay."  #CytoDyn #Oncology #Leronlimab #TNBC #ColorectalCancer #CCR5 cytodyn.com Listen to the podcast here

Diese Low Budget Kurzfilmdoku von Anna Zhukovets & Karen Abel wurde zwischen 2021 ( Karen hatte gerade die Untersuchungsergebnisse bekommen 3 Jahre mit einem Medikament stabil zu sein) und 2022 ( mitten im 2. Progress, das heißt der Tumor und die Metastasierung breiten sich aufgrund der Resistenz gegenüber der Behandlung aus) gefilmt. Inzwischen hat Karen schon den 4. Progress hinter sich:Die Regisseurin, Editorin, Fotografin und Journalistin Anna Zhukovets (Geboren 1997 in Mariupol; Vita unter https://www.hff-muc.de/de_DE/studente... ) schafft es innerhalb eines Jahres das Leben einer Frau – die niemals aufgibt - mit dem Lungenkrebs einzufangen. Dabei unterstützt Karen Anna inhaltlich und auch kreativ im gesamten Filmprozess.Wissbegierde, Offenheit, Loyalität und eine unermüdliche Selbstarbeit: Das ist Karen Abel. Gerade im Dokumentarfilm lernt man von jedem Menschen etwas. Von Karen lerne ich, mich mehr in Dankbarkeit und Optimismus zu üben. Von Anfang an, lehnt Karen Mitleid ab. Mitgefühl statt Mitleid. Das wünscht sie sich. Offene Fragen statt Stille. Zuhören. Wie hört man empathisch zu? Wie wird man einem persönlichen Portrait gerecht? Indem ich mich als Filmemacherin zurücknehme. Nur so kann man zuhören. Lungenkrebs, das ist die Krankheit der Zukunft. Sie betrifft uns alle. Familie, Freunde und Partner: Die Stigmata des rauchenden alten Mannes hemmt oft einen offenen Diskurs. Und es stimmt nicht. Immer mehr junge Nicht- und Nie Raucher sind betroffen. Ein Film, der die Vorurteile über Lungenkrebs entkräftet. Und gleichzeitig sichtbar macht. Nämlich: Die Geschichte von Karens und Vesnas '' Wie Phönix aus der Asche'' soll sich der eigenen Lebenskraft und Endlichkeit nähern.''Wie Phönix aus der Asche'' ist eine Film-Odyssee. Anna Zhukovets und Karen Abel machen sich auf die Suche nach den Tiefen der Krebsforschung. Sprechen mit Experten und Betroffenen, ohne zu erahnen, dass es sich bei dieser Reise durch die Wissenschaft um die eigene Reflexion dreht. Um den Tod und das Leben. ''Wie Phönix aus der Asche'' ist eine Erzählung einer Frau, die scheinbar dem Tod geweiht ist. Und dennoch: Nicht aufhören will die bestehenden Regeln der Medizin zu hinterfragen. Die Geschichte von Karen Abel, sie zeigt, wie sehr es sich lohnt, zu hinterfragen. Nach anderen Wegen zu suchen. Die Geschichte trägt die Erkenntnis mit sich, dass die Krebsforschung mehr kann als nur Strahlen- und Chemotherapie. Für Karen Abel muss sie ganzheitlich sein. Sie muss den Menschen im Kern mitdenken. Dafür muss die Ärzte-Patient: innen-Kommunikation auf Augenhöhe bleiben.Chapters00:00 Der Weg zur Selbstakzeptanz02:38 Stigmatisierung und die Realität von Lungenkrebs06:11 Die Entstehung von Lungenkrebs08:45 Die Herausforderungen der Diagnose12:03 Die Bedeutung von Lebensqualität und Achtsamkeit14:49 Der Umgang mit dem Tod und die Rolle der Ärzte

Will Bridges https://www.imdb.com/name/nm2782297/ shares his method for making every meeting an opportunity. And he explains what he did that let him come from 10 years of working random jobs and trying to make shorts here and there, to becoming the newly discovered talent, suddenly writing for hit series like “Black Mirror” and “Stranger Things” as well as being a co-creator with Charlie Brooker.Matt and Oren get Will to open up about what he learned from "Shaun of the Dead" and how those filmmakers pitched. And they break down the process of showing decision-makers a concept and the steps needed to get them to truly understand what it will look like, feel like, and clearly see the audiences it will resonate with.If you're looking for ideas to improve how you direct actors, you too will get a lot from this episode. And Will goes into the secret of freeing up established actors to do their best work. And he's got some warnings about key mistakes many directors often make---Help our Patreon! https://www.patreon.com/JustShootItPodMatt's Endorsement: "Paprika" https://www.imdb.com/title/tt0851578Oren's Endorsement: Mike Birbiglia's "Working It Out" podcast https://www.podpage.com/mike-birbiglias-working-it-out/ and Za'atar spice https://en.wikipedia.org/wiki/Za'atarWill's Endorsement: "Tumor", the graphic novel https://en.wikipedia.org/wiki/Tumor_%28comics%29 Hosted on Acast. See acast.com/privacy for more information.

Rainer Langhans sitzt vor mir. 85 Jahre alt, Prostatakrebs im Endstadium. Der letzte Überlebende der berüchtigten Kommune 1. 1967 gründete er mit ein paar Hippies die erste deutsche Wohngemeinschaft: Freie Liebe, kollektives Leben, totale Revolution. Die Medien überschlugen sich, Deutschland war schockiert. Dann kam der Wendepunkt: Seine Mitstreiter griffen zu Bomben. Aus Hippies wurden Terroristen. Die RAF entstand aus den Trümmern der Friedensbewegung. Rainer verweigerte die Gewalt - und wurde zum Verräter erklärt. Heute, 57 Jahre später, hat er Krebs. Aber statt zu kämpfen, feiert er seinen Tumor als Geschenk der Liebe. Er will sterben lernen, um richtig zu leben. Während andere Angst vor dem Tod haben, sehnt er das Ende herbei. Ich wollte wissen: Was passiert, wenn wir aufhören, den Tod zu fürchten? ---------- Sponsoren: (WERBUNG) https://linktr.ee/ungeskriptet_werbepartner Aufnahmedatum: 5. November 2025 KAPITEL: (00:00:00) - Intro (00:01:51) - Warum junge Rebellen zu Spießern werden (00:08:08) - Die 68er-Liebeserfahrung: Ein Jahr im Paradies (00:16:49) - Vom Autisten zum Revolutionär (00:23:29) - Krebs als Liebesgeschenk (00:36:40) - Keine Kontrolle über das Schicksal (00:46:10) - Autismus: Als Dreijähriger wusste ich, ich bin anders (00:52:00) - Sterben lernen: Der Weg zur wahren Spiritualität (01:08:55) - 68er vs. heute: Warum sich Geschichte wiederholt (01:17:18) - Kindheit im Krieg: Streit mit dem Vater (01:28:00) - Von Liebe zu Bomben: Wie Hippies zu Terroristen wurden (01:41:18) - Hitler und das Dritte Reich: Der Traum vom neuen Menschen (01:47:17) - Meditation und Meister: Der unmögliche Weg nach innen (01:57:30) - Eine letzte Frage Ben: Youtube: https://www.youtube.com/c/ungeskriptetbyben?sub_confirmation=1 TikTok: https://www.tiktok.com/@ungeskriptet Instagram: https://instagram.com/ben_ungeskriptet X: https://x.com/benungeskriptet?s=21 Rainer: Website: https://rainerlanghans.de/ https://www.nach-innen.com/ Youtube: https://www.youtube.com/@TheRiefenstahl {ungeskriptet} gibt's hier bei YouTube und überall, wo es Podcasts gibt. Alle weiteren Links: https://www.ungeskriptet.com Mein Ziel ist, der beste Podcast Host Deutschlands zu werden. Ich verspreche dir, die spannendsten Gäste an meinen Tisch zu holen. 100% Realtalk. No Bullshit. #besterpodcast. Learn more about your ad choices. Visit megaphone.fm/adchoices

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ 00:00:00 - Intro - Foods - Dr. Morse History 00:18:05 - Tumors  00:29:58 - Reincarnation 00:18:05 - Tumors  I'm a 50 year old female, and have a lump in my breast and head.  00:29:58 - Reincarnation When our bodies pass and we come into a new body in our next life — does any of the work we did on the body in this lifetime, pass to the next?

Hi friends! So thankful to be back with you guys today :) In this episode , I answer some more of your questions! We talk about my pituitary tumor symptoms, how to start recovery, coping when it's dark and cold outside, and my thoughts on "full" ed recovery. I hope this episode brings you peace! I'm so thankful for you!GabbiXx

To Health With That! Podcast Season 5, Episode 5. Thank you so much to Tony for generously sharing his story - the full interview was fabulous and included much more than we could put in one podcast episode, so we broke it into two. In this episode, Tony continues to share with the idea of MTHFR being a rebirth, new information he has about a tumor and his concerns about folate and tumor growth, and questions about MTHFR and anesthesia.00:00 - Introduction00:43 - Manageable steps01:07 - Symptom tracking01:23 - Staying in control (or not).02:03 - MTHFR as a rebirth02:45 - tumor03:10 - folate and tumor growth04:40 - Do we get enough B12 from food06:15 - B12 and lithium rotate07:15 - MTHFR and detox09:42 - mental health struggles and folic acid10:31 - MTHFR and anesthesia11:11 - MTHFR and nitrous oxide and preparing for surgery12:32 - MTHFR and antibiotics13:33 - Building back good gut floraThanks so much for watching! I have so many other resources for you. Here is the full version of this interview: https://youtu.be/SZmHnyCKd8UIf you would like to tell your own MTHFR story, you can schedule with Dr. Amy here: ⁠https://calendly.com/amy-tohealthwiththat/new-meeting⁠Check out the website first for lots of FREE stuff:WEBSITE: https://tohealthwiththat.com/ You can now Pre-order the book MTHFR Easy: Get Healthy For Life. https://www.amazon.com/MTHFR-Get-Started-Guide-Healthy-ebook/dp/B0FLFCY1YQ/ref=sr_1_2?crid=3E616JJOYSA12&dib=eyJ2IjoiMSJ9.7WXbrOZ6vkAu5Ncg9lJLavpPvim_O1kOvqp3LTim_snTq6Gahvu-NhWvC1mZurA6.XnOpY_FYGI_DbfEx9NmEwRrSM2USTXkw_HTykBFrMtw&dib_tag=se&keywords=amy+neuzil&qid=1755710249&sprefix=amy+neuzil%2Caps%2C98&sr=8-2 Look for Kindle, audiobook, and paperback versions also to be released on October 24, 2025.GENETIC ROCKSTARS (an MTHFR, methylation, and genetics community): https://community.tohealthwiththat.comThis story was shared graciously and generously with permission to post on the podcast, Youtube, and in print if that happens in the future.

Ian shares a bit of absolutely unofficial medical advice that you should only follow if you want a laugh

It could be a bug bite. Or a harmless fatty lump. But it might be a mast cell tumor. In this episode of the VetFolio Voice podcast, we delve into mast cell tumors in dogs, including the unpredictable nature of these tumors, nuances around interpretation of cytology and histopathology reports, cytologic grading accuracy, and options for therapy including surgery, chemo, radiation and Stelfonta, an injectable mast cell tumor treatment for dogs. You'll learn about staging considerations and the role of newer prognostic panels as well as strategies for client communication about mast cell disease.

❣ Gratis 7 Tage Ernährungsplan nach Glykoplan: Hier klicken❣ Galactose: Hier klicken (✔ 10 % CODE: TAN34909)Die Datenlage ist klar: Zuckerarme oder zuckerfreie Ernährung mit wenig Kohlenhydraten und guten Fetten hilft immer, egal ob bei Alzheimer, Parkinson oder sogar Krebst. Dr. med. Kurt Mosetter zeigt auf, dass es mittlerweile 56 verschiedene Bezeichnungen für Zucker gibt und wie du dich ernähren kannst, sodass die Zellen und dein Körper sich selbst reparieren. Danke an @swissbiohealthkreuzlingen3586 für das herausragende Therapeutentreffen. ✨ Mehr Infos zu Dr. Kurt Mosetter: Kurts Homepage: https://www.myoreflex.de/Der Glycoplan: Hier klickenInhaltsverzeichnis: 00:00 Intro 02:36 DAS hemmt Tumorzellen? 07:12 Bioelektrische Felder steuern 09:48 Epigenetische Reparaturmechanismen 12:24 Natursubstanzen fördern Gesundheit✨ Mehr mr.broccoli: Blog YouTube Instagram Telegram-Community (für besonders brisante Themen) Newsletter▶▶▶ Meine 10 Favoriten für mehr Gesundheit

In this episode of SurgOnc Today, Mark Knab, Charles Vining, and Kelvin Allenson discuss how the anatomic location of duodenal adenocarcinoma—from the first to the fourth portion—fundamentally shapes surgical decision-making. Discussion highlights include criteria for pancreaticoduodenectomy versus segmental or limited resections, the role of margin status and lymphadenectomy, and evolving data guiding resection strategy for non-ampullary duodenal cancers. Designed for practicing surgical oncologists, this episode emphasizes operative judgment, outcomes data, and the balance between oncologic adequacy and surgical morbidity.

Shirts, long sleeves, and hoodies are back for a limited time! This batch has the podcast logo on the back and on the front is a simple name tag saying "Dental Technician". Be proud of what you do and show the WORLD that we exist. Shirts on sale until November 8, 2025. As always 100% of the profits go towards the Foundation For Dental Laboratory Technology (https://dentallabfoundation.org/)! https://www.bonfire.com/its-all-in-the-name160/ This week, Elvis and Barb cross the globe to chat with the legendary Marc Rondeau—a Sydney-based dental technician, educator, and yes, nightclub DJ. From being one of 30 accepted out of 300 applicants into Australia's only dental tech program, to running one of the country's top labs, Marc's journey is packed with hard work, humor, and heart. He shares how a near-fatal car accident—and the brain tumor it uncovered—completely reshaped his perspective on work-life balance, pushing him to give back through teaching and advocacy. Now the Vice President of the Australian Dental Technicians Association (https://www.australiandentaltechnicians.com.au/), Marc talks about the fight to keep technicians recognized, the shift from analog to CAD/CAM, and why he believes every tech should know how to “wax before they CAD.” * Dental Labs—The Ivoclar (https://www.ivoclar.com/en_us) Flash Sale Is On! * From November 3rd to 14th, Ivoclar is bringing you unbeatable deals on the equipment that will set your lab up for success in 2026. * Upgrade your mill, your furnace, or expand your workflow—and save big while doing it! * Plus, when you purchase a milling machine (https://www.ivoclar.com/en_us/products/product-list?page=1&limit=12&filters=%5B%7B%22id%22%3A%22professions%22%2C%22advancedFilter%22%3Afalse%2C%22values%22%3A%5B%22Lab%22%5D%7D%2C%7B%22id%22%3A%22categories%22%2C%22advancedFilter%22%3Afalse%2C%22value%22%3A%22Digital%20Equipment%22%7D%5D), you'll get delivery, installation, and training—all included. That means your lab will be production-ready from day one. * But hurry—these savings vanish after November 14th! * Contact your Ivoclar sales rep today and power up your lab for the year ahead. The right CAM software can completely transform your lab's workflow — and no one understands that better than FOLLOW-ME! Technology (https://www.follow-me-tech.com/), creators of hyperDENT (https://www.follow-me-tech.com/hyperdent/#product_overview). That's why Roland DGA (https://www.rolanddga.com/applications/dental-cad-cam) has partnered with FOLLOW-ME! North America to offer the Roland DGA x hyperDENT Bundle for their DWX-53D series mills. This collaboration gives labs optimized performance, smoother milling, and incredible efficiency gains — with some users reporting up to two hours saved per case cycle without sacrificing quality. And here's the best part: Roland is making this available to everyone through a hyperDENT trade-in promo for existing users. It's the perfect opportunity to upgrade your CAM and take full advantage of the technology you already have. Plus, Nowak Dental Supplies (https://www.nowakdental.com/) is participating in the promotion and adding an exclusive bonus for NOLA Lab Fest attendees: the Multiple Instances feature at no additional cost. Don't miss your chance to see the difference in person! Join Jordan Greenberg — the “hyperDENT dude” himself — at NOLA Lab Fest, November 7–8 (https://www.nolalabfest.com/), and discover how CAM can redefine what your Roland mill can do. Special Guest: Marc Rondeau.

Linktree: ⁠https://linktr.ee/Analytic⁠Join The Normandy For Additional Bonus Audio And Visual Content For All Things Nme+! Join Here: ⁠https://ow.ly/msoH50WCu0K⁠In this Notorious Mass Effect segment, Analytic Dreamz delivers a comprehensive analysis of Rosalía's groundbreaking 2025 single “Berghain” featuring Björk and Yves Tumor, the lead track from her upcoming album Lux, releasing November 7 via Sony Music. Clocking in at 3:26, the Nicolás Méndez-directed video amassed 3M+ YouTube views in 24 hours and 6M+ by October 29, hitting #2 globally on Trending while debuting Top 5 on Spotify Spain and trending in Germany, Iceland, and Latin America. Filmed across Berlin and Barcelona, the multilingual masterpiece in German, English, and Spanish blends organ, choir, synth bass, and London Symphony Orchestra strings conducted by Daníel Bjarnason. Analytic Dreamz dissects symbolic scenes—from Catholic iconography and a wounded heart jewel to Snow White animal motifs, a dissolving sugar cube nod to Kieslowski's Three Colors: Blue, and a white dove ascension signifying rebirth post-heartbreak with subtle Rauw Alejandro references like the fox and garnet medallion. Fashion highlights include archival Alexander McQueen Fall 2002 shredded dress, Spring 2003 rosary sandals, Givenchy Spring 1997 fringed top, and Balenciaga Spring 2004 cutout piece, curated by José Carayol to evoke holiness and reincarnation. Lux's 18-song, four-movement structure features collaborators Carminho, Estrella Morente, Silvia Pérez Cruz, and shifts from Motomami's urban edge to orchestral spirituality, with 300K+ pre-saves and 1.2M+ Instagram likes signaling massive impact. Analytic Dreamz explores lyrics like “Ich halte viele Dinge in meinem Herzen” and Björk's “divine intervention” bridge, positioning “Berghain” as Rosalía's boldest evolution yet.Support this podcast at — https://redcircle.com/analytic-dreamz-notorious-mass-effect/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Featuring an interview from Dr John Strickler, including the following topics: Prognostic value of molecular residual disease (MRD) as detected by circulating tumor DNA (ctDNA) and optimal incorporation of MRD assays into the care of patients with colorectal cancer (0:00) Potential use of MRD assays for patients with microsatellite instability (MSI)-high localized colorectal cancer or those with delayed progression or metastatic disease (16:09) Tumor-informed MRD assays under clinical development (20:36) Predictive role of ctDNA in Stage III colon cancer treated with celecoxib; effect of low-dose aspirin on response to celecoxib in patients with PI3K pathway alterations (24:19) Case: A man in his late 50s with resected Stage IIA colon cancer (30:06) Case: A woman in her late 40s with Lynch syndrome and MSI-H colon cancer with a solitary, small hepatic metastasis (34:57) MRD as a future clinical trial endpoint for solid tumors; increasing incidence of colorectal cancer in younger people (40:24) Antibody-drug conjugates in the treatment of colorectal cancer (45:13) Perspectives on promising areas of clinical research in colorectal cancer (48:23) CME information and select publications

In this episode of JCO PO Article Insights, host Dr. Jiasen He summarizes the article, "Somatic Mutation Profiles of Colorectal Cancer by Birth Cohort" by Gilad, et al published October 11, 2025. TRANSCRIPT Jiasen He: Hello, and welcome to the JCO Precision Oncology Article Insights. I am your host, Jiasen He, and today, we will be discussing the JCO Precision Oncology article, "Somatic Mutation Profiles of Colorectal Cancer by Birth Cohort," by Dr. Gilad and colleagues. Early-onset colorectal cancer is defined as colorectal cancer diagnosed before the age of 50. Several reports have suggested that early-onset colorectal cancer has unique characteristics. Compared with late-onset colorectal cancer, early-onset colorectal cancer cases are more commonly found in the distal colon or rectum, tend to be diagnosed at more advanced stages, and may display unfavorable histologic features. Although the overall incidence of colorectal cancer has declined in recent decades, the incidence of early-onset colorectal cancer continues to rise. This increase appears to be driven by birth cohort effects. The reasons behind this rise remain unclear but are likely multifactorial, involving changes in demographics, diet, lifestyle, environmental exposures, and genetic predisposition. At the same time, studies have shown conflicting results regarding whether there are differences in the mutation profiles between early-onset and late-onset colorectal cancer. Therefore, it is crucial to explore whether colorectal cancer somatic mutational landscape differs across birth cohorts, as this could provide important insight into generational shifts in colorectal cancer incidence. To address this question, the authors conducted a retrospective study to characterize the mutation spectrum of colorectal cancer across different birth cohorts. Consecutive colorectal cancer patients who underwent somatic next-generation sequencing at the University of Chicago pathology laboratory between 2015 and 2022 were retrospectively identified. Tumors were tested for 154 to 168 genes and categorized as either microsatellite stable or high according to established thresholds. Patients with hereditary cancer syndromes or inflammatory bowel disease were excluded. Participants were then grouped into birth cohorts by decades, as well as into two major groups: those born before 1960 and after 1960. Genes that were identified in at least 5% of the sample were selected and grouped into 10 canonical cancer signaling pathways. These genes and pathways were then included in the analysis to explore their association with colorectal cancer across different birth cohorts and age groups. A total of 369 patients were included in the study, with a median birth year of 1955 and a median age at colorectal cancer diagnosis of 62.9 years. 5.4% were identified as having microsatellite-high tumors. The median tumor mutational burden was 5 mutations per megabase for microsatellite-stable tumors and 57.7 mutations per megabase for microsatellite-high tumors. Patients with microsatellite-high tumors tended to have earlier birth years and were diagnosed at an older age. However, after adjusting for potential confounders, neither birth year nor age remained statistically significant. Similarly, after controlling for confounders, no significant associations were observed between birth year or age and mutation burden. In this cohort, APC, TP53, and KRAS were the most frequently mutated genes. No statistically significant differences in the prevalence of gene mutations were observed across birth cohorts. Correspondingly, the most affected signaling pathways were the Wnt, TP53, and (RTK)/RAS pathways. Similar to the gene-level finding, no significant differences in the prevalence of these pathways were identified among birth cohorts. When examining patients born before and after 1960, the authors found that the older birth cohorts were diagnosed at an older age and had higher tumor mutational burden. However, no significant differences were observed in any of the genes or pathways analyzed. Among microsatellite-stable tumors, 18.3% were classified as early-onset colorectal cancer, while 81.1% were late-onset colorectal cancer. Consistent with previous reports, early-onset colorectal cancers in this cohort were more likely to be left-sided and more common among more recent birth cohorts. However, no significant differences were identified in any of the examined genes or pathways when comparing early-onset to late-onset colorectal cancer. In this cohort, a higher prevalence of early-onset colorectal cancer was observed among more recent birth cohorts, consistent with previous reports. Still, no distinct mutational signature was identified between the early and late birth cohorts. The authors proposed that the lack of distinct mutational profile by age or birth cohort may be due to the limited number of key molecular pathways driving colorectal cancer. Although environmental exposures likely differ across generations, the downstream effects may have converged on similar biological mechanisms, leading to comparable somatic mutations across cohorts. Alternately, they proposed that the observed birth cohort differences in colorectal incidence may be driven by distinct mutation signatures, epigenetic alterations, or changes in the immune microenvironment rather than variations in canonical gene mutations. As the authors noted, given the retrospective nature of this study, its modest sample size, and the predominance of advanced-stage tumors, larger prospective studies are needed to validate these findings. In summary, this study found no significant differences in the mutational landscape of colorectal cancer across birth cohorts or age groups. The authors proposed that the generational shift in colorectal cancer incidence is unlikely to be driven by changes in the underlying tumor genomics. However, larger prospective studies are needed to validate these findings. Thank you for tuning in to JCO Precision Oncology Article Insights. Do not forget to subscribe and join us next time as we explore more groundbreaking research shaping the future of oncology. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

#ROSALÍA #Björk #YvesTumor #Latin #PopSeason 11 BEGINS! For Let's Talk About It: MUSIX REVIEWS. The Music Critic is gearing up ready to deliver a action packed season. Daily episodes are fully back! This SEASON is the first yearly long season! Get ready for the wild RIDE OF S11! Fun Pop Reviews, Rap Reviews AND MORE! ROSALÍA, Björk, Yves Tumor, Berghain, music collaboration, electronic music, avant-garde pop, experimental artists, music video, live performance, underground music, Spanish singer, Icelandic artist, alternative music, modern music, club culture, music reviews, genre fusion, indie music

Are cats the forgotten patients in oncology? Dr. Sue Ettinger is back on the Purr Podcast to elaborate on cancer tests, treatments, and why cats deserve more. Why are clinical trials and funding so limited for cats? What is the next big leap in feline oncology? What is the best practice for early cancer detection in cats? Dr. Sue Cancer Vet joins our hosts, Dr. Susan Little and Dr. Jolle Kirpensteijn, live from WVC 2025 to tackle one of veterinary medicine's biggest questions: Why are cancer diagnostics and treatments for cats lagging behind dogs?Thanks for tuning in to the Purr Podcast with Dr. Susan and Dr. Jolle!If you enjoyed today's episode, don't forget to subscribe, rate, and leave us a review—it really helps other cat lovers and vet nerds find the show. Follow us on social media for behind-the-scenes stories, cat trivia, and the occasional bad pun. And remember: every day is better with cats, curiosity, and maybe just a little purring in the background. Until next time—stay curious, stay kind, and give your cats an extra chin scratch from us. The Purr Podcast – where feline medicine meets feline fun.

Dr. Brooke Britton discusses degranulation events—a scary potential when a dog has mast cell tumors. Learn what degranulation is, why it happens, and how it can affect your dog. Also: practical tips for managing symptoms, potential connections between allergies and cancer, and how to care for dogs with mast cell tumors. Topics Discussed: • What is a degranulation event? • How mast cell tumors cause degranulation • Symptoms dogs may experience during a degranulation event • The role of allergies and chronic inflammation in mast cell tumor risk • Medications and treatments to manage symptoms • Low-histamine diets and their role in comfort care • Tips for preventing future mast cell tumor growth • The importance of early detection and regular vet check-ups Your Voice Matters! If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Videos: https://www.youtube.com/watch?v=Al7jjCXVhuE https://www.youtube.com/watch?v=6eb4GrcH_f8 Related Links: Our article on mast cell tumors: https://www.dogcancer.com/articles/types-of-dog-cancer/mast-cell-tumors-in-dogs/ Chapters: 00:00 Introduction 01:15 What Are Mast Cell Tumors? 02:30 The Role of Mast Cells in Normal Immune Response04:00 What Happens During a Degranulation Event?06:45 Symptoms Dogs May Experience During Degranulation09:00 How Dogs Might Feel During Degranulation Events11:00 Stomach Upset and Ulcers in Dogs with Mast Cell Tumors13:00 The Link Between Allergies and Mast Cell Tumors16:00 Managing Allergies in Dogs to Reduce Risk18:30 Diet Considerations: Low-Histamine and Commercial Diets22:00 Medications for Degranulation Symptoms: Benadryl and Tagamet25:00 The Truth About Diet and Cancer Prevention27:30 Why Balanced Diets Are Key for Dogs with Cancer29:45 Closing Thoughts on Degranulation and Mast Cell Tumors34:00 Outro: Support and Resources for Dog Owners Get to know Dr. Brooke Britton: https://www.dogcancer.com/people/brooke-britton-dvm-dacvim-oncology/    For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Tumor components and immune response indicators can be found in cerebrospinal fluid, or CSF, when someone has a brain tumor, in a new test developed by Chetan Bettagowda, director of neurosurgery at Johns Hopkins and one of the test's developers.  … Cerebrospinal fluid may hold the keys to brain cancer identification and treatment, Elizabeth Tracey reports Read More »

In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.

This is a text-to-speech (TTS) AI reading of our most recent blog post: 6 Facts Every Clinician Needs to Know About Tumor Lysis Syndrome.https://www.pointofcaremedicine.com/blog-post/6-facts-every-clinician-needs-to-know-about-tumor-lysis-syndrome-2025Tumor Lysis Syndrome (NEJM, 2025)Bociek RG, Lunning M. Tumor Lysis Syndrome. N Engl J Med. 2025;393(11):1104-1116. doi:10.1056/NEJMra2300923‍Related ContentTumor Lysis Syndrome Admission Template

About the size of a BASEBALL!!!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

BUFFALO, NY – October 20, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on October 16, 2025, titled “Widespread folate receptor expression in pediatric and adolescent solid tumors – opportunity for intraoperative visualization with the novel fluorescent agent pafolacianine.” In this study, led by first author Ashley C. Dodd from Ann & Robert H. Lurie Children's Hospital and corresponding author Timothy B. Lautz from the same institution and Northwestern University Feinberg School of Medicine, researchers discovered that folate receptor beta (FRβ) is widely expressed in various pediatric and adolescent solid tumors. This finding highlights FRβ as a promising target for improving the accuracy of tumor surgery using a fluorescent imaging agent known as pafolacianine. Pediatric cancers are often challenging to remove completely during surgery, particularly when tumors spread or form small metastases. Fluorescence-guided surgery is a method that helps surgeons better identify tumors during operations using special imaging dyes. However, commonly used dyes such as indocyanine green are not tumor-specific and rely on general features of blood vessel permeability, limiting their precision. In this study, researchers investigated the potential of pafolacianine, a next-generation dye that targets folate receptors, for pediatric use. Folate receptors are proteins commonly found on the surface of cancer cells. Pafolacianine is already FDA-approved for adults with ovarian and lung cancers due to its ability to bind these receptors and highlight tumors during surgery. The research team analyzed tissue samples from 13 young patients diagnosed with various cancers, including Wilms tumor, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, Ewing sarcoma, and neuroblastoma. The results showed that FRα was predominantly absent, whereas FRβ was present in 100% of the tumor samples. Notably, FRβ appeared both on the tumor cells and in the surrounding tumor microenvironment but showed little to no expression in normal tissue, making it an excellent candidate for targeted imaging. “In this study, we performed immunohistochemistry staining on slides obtained from a range of pediatric patients with solid tumors.” This consistent expression of FRβ in pediatric tumors is a significant and novel finding. Earlier studies primarily linked FRβ to immune cells called tumor-associated macrophages. This study reveals that FRβ is also expressed directly on tumor tissue, which could help surgeons better distinguish cancer from healthy tissue during procedures. Based on these results, the team has launched a clinical trial to evaluate pafolacianine in children undergoing surgery for metastatic lung tumors. If successful, this method could make pediatric cancer surgery safer and more effective. Overall, this study suggests that targeting FRβ with pafolacianine could serve as a tumor-agnostic imaging strategy, applicable across a wide range of pediatric solid tumors. This represents a potential advancement in real-time surgical imaging and a step forward in pediatric cancer care. DOI - https://doi.org/10.18632/oncotarget.28772 Correspondence to - Timothy B. Lautz - TLautz@luriechildrens.org Abstract video - https://www.youtube.com/watch?v=0its0QkOcwM Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Nuestro guía por la sanidad pública, el nefrólogo Borja Quiroga, nos conduce hasta Dani, el paciente con tumor de páncreas que ayudó a desvelar chatGPT. ¿Cómo puede la IA dar superpoderes a los médicos? Conversamos con un experto en la aplicación de la IA en la sanidad, el neurólogo y director de Savana Ignacio Hernández Medrano.

In this episode of Healthy Mind, Healthy Life, host Avik welcomes Riza August, who shares her inspiring journey of resilience and self-discovery following a brain tumor diagnosis. Riza discusses her decision to reclaim her life through an 1845-mile bike journey, the emotional and spiritual growth she experienced, and the importance of sharing her story to help others heal. The conversation emphasizes the power of perspective, the significance of taking small steps towards recovery, and the ongoing journey of personal transformation. Takeaways Riza made a conscious decision to live after her diagnosis. The bike journey was a spiritual testament to perseverance. Healing can be facilitated through sharing one's story. Vulnerability is a powerful form of medicine for the soul. Asking 'What can I do?' can shift one's perspective. Even small steps can lead to extraordinary outcomes. Riza's journey opened her up to new experiences and opportunities. Embracing change is essential for personal growth. Healing and growth are lifelong practices. We are all worthy of healing and transformation.   Chapters 00:00 Introduction to Riza's Journey 02:02 The Decision to Live 03:44 Reflecting on Life's Choices 05:23 The Spiritual Journey of Biking 06:49 Healing Through Sharing 09:51 Overcoming Limitations 12:19 Embracing Change and Growth 13:46 Continuing the Journey of Transformation   Watch Video: https://youtu.be/XHyzG1sC-ns    Reach Risa: Facebook: https://www.facebook.com/risa.august.unleashed/ Instagram: https://www.instagram.com/risaunleashed/ LinkedIn: www.linkedin.com/in/risa-august-9b130524a      Disclaimer: This video is for educational and informational purposes only. The views expressed are the personal opinions of the guest and do not reflect the views of the host or Healthy Mind By Avik™️. We do not intend to harm, defame, or discredit any person, organization, brand, product, country, or profession mentioned. All third-party media used remain the property of their respective owners and are used under fair use for informational purposes. By watching, you acknowledge and accept this disclaimer.   -----   Healthy Mind By Avik™️ is a global platform redefining mental health as a necessity, not a luxury. Born during the pandemic, it's become a sanctuary for healing, growth, and mindful living. Hosted by Avik Chakraborty storyteller, survivor, wellness advocate this channel shares powerful podcasts and soul-nurturing conversations on:   • Mental Health & Emotional Well-being • Mindfulness & Spiritual Growth • Holistic Healing & Conscious Living • Trauma Recovery & Self-Empowerment   With over 4,500+ episodes and 197.4K+ global listeners, join us as we unite voices, break stigma, and build a world where every story matters.  

Cats deserve cancer breakthroughs too! Dr. Sue Ettinger, DVM, DACVIM (Oncology), shares what's on the horizon for feline cancer testing in the next episode of the Purr Podcast. Known on social media as Dr. Sue Cancer Vet, she is an international speaker, author, & vlogger. She is a board-certified specialist in medical oncology. She received her veterinary training at Cornell University College of Veterinary Medicine. She completed her residency in medical oncology at the Animal Medical Center in NYC in 2003.Thanks for tuning in to the Purr Podcast with Dr. Susan and Dr. Jolle!If you enjoyed today's episode, don't forget to subscribe, rate, and leave us a review—it really helps other cat lovers and vet nerds find the show. Follow us on social media for behind-the-scenes stories, cat trivia, and the occasional bad pun. And remember: every day is better with cats, curiosity, and maybe just a little purring in the background. Until next time—stay curious, stay kind, and give your cats an extra chin scratch from us. The Purr Podcast – where feline medicine meets feline fun.

BUFFALO, NY – October 14, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on October 13, 2025, titled “Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields.” The study, led by Hugo Jimenez from Wayne State University School of Medicine, Karmanos Cancer Institute, introduces a novel treatment approach for glioblastoma, an aggressive and often treatment-resistant brain cancer. The findings open a new potential path for patients who currently have limited therapeutic options. The approach uses a device developed by TheraBionic that delivers extremely low levels of radiofrequency electromagnetic fields, tuned to frequencies associated with glioblastoma. In laboratory experiments, this therapy significantly slowed the growth of multiple glioblastoma cell lines. It was especially effective against tumor stem cells, which are known to resist standard treatments and drive cancer reappearance. Researchers also found that the treatment's effects depend on a calcium channel in tumor cells known as Cav3.2 (CACNA1H). When this channel was blocked, the therapy lost its effectiveness, highlighting the channel's essential role in how tumor cells respond to the signal. The therapy also disrupted the process of cell division by interfering with the mitotic spindle, a structure critical for cell replication. This disruption was associated with changes in the expression of genes that regulate cell division, particularly those involved in the “Mitotic Roles of Polo-Like Kinase” pathway. These effects were specific to tumor-targeted frequencies, as non-matching signals had no measurable impact. The study also includes data from two patients with difficult-to-treat brain tumors who received the therapy through compassionate use. One patient with recurrent glioblastoma showed signs of clinical and radiographic improvement after one month of treatment. Another patient with oligodendroglioma tolerated the therapy well and had stable disease during follow-up imaging. Neither patient experienced serious side effects, further supporting the safety of the therapy. “There was evidence of clinical and radiological benefit in a 38-year-old patient with recurrent GB and evidence of safety and feasibility in a 47-year-old patient with oligodendroglioma.” This is the first study to demonstrate that tumor-specific radiofrequency therapy can suppress both tumor growth and cancer stem cells in glioblastoma. Similar results had previously been observed in liver and breast cancers. These findings contribute to the growing body of evidence supporting a new class of systemic, non-toxic cancer therapies. Further clinical trials will be crucial to confirm these results and fully assess the potential of this approach for treating brain cancer. DOI - https://doi.org/10.18632/oncotarget.28770 Correspondence to - Hugo Jimenez - hugo.jimenez@wayne.edu Abstract video - https://www.youtube.com/watch?v=uxYnWcNKYfg Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28770 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, oncology, amplitude-modulated radiofrequency electromagnetic fields, glioblastoma, TheraBionic, CACNA1H, Cav3.2 To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Check your ego at the door! In this BackTable MSK Brief, Dr. Mark Amsbaugh and Dr. Ran Lador share their multidisciplinary approach to the treatment of spinal tumors at the University of Texas and Memorial Hermann in Houston. They highlight the distinctive aspects of their practice, including their extensive collaboration and support system for patients, the intricate process of managing spinal tumors, and the unique challenges and solutions they encounter. The doctors emphasize the importance of teamwork, minimally invasive techniques, and comprehensive patient-centered care to improve treatment outcomes for patients with spinal tumors. Episode Outline 00:00 - Introduction  03:18 - Addressing Potential Barriers in Receiving Spinal Tumor Treatment 04:32 - The Multidisciplinary Approach in Action 07:46 - Minimally Invasive Techniques and Their Impact 09:49 - Navigating Patient Care and Referrals 14:29 - Final Thoughts  Resources Dr. Mark Amsbaugh, MD https://med.uth.edu/neurosciences/dr-mark-j-amsbaugh-md/  Dr. Ran Lador, MD https://med.uth.edu/ortho/2022/11/02/ran-lador-md/  Dr. Alexa Levey, MD https://medicine.yale.edu/profile/alexa-levey/

Dr. Hope Rugo and Dr. Giuseppe Curigliano discuss recent developments in the field of bispecific antibodies for hematologic and solid tumors, including strategies to optimize the design and delivery of the immunotherapy. TRANSCRIPT Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center. I am also the editor-in-chief of the Educational Book. Bispecific antibodies represent an innovative and advanced therapeutic platform in hematologic and solid tumors. And today, I am delighted to be joined by Dr. Giuseppe Curigliano to discuss the current landscape of bispecific antibodies and their potential to reshape the future of precision oncology. Dr. Curigliano was the last author of an ASCO Educational Book piece for 2025 titled, "Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances." Dr. Curigliano is a breast medical oncologist and the director of the Early Drug Development Division and chair of the Experimental Therapeutics Program at the European Institute of Oncology in Milan. He is also a full professor of medical oncology at the University of Milan. You can find our disclosures in the transcript of this episode. Dr. Curigliano, Giuseppe, welcome and thanks for being here. Dr. Giuseppe Curigliano: Thanks a lot for the invitation. Dr. Hope Rugo: Giuseppe, I would like to first ask you to provide some context for our listeners on how these novel therapeutics work. And then perhaps you could tell us about recent developments in the field of bispecific antibodies for oncology. We are at a time when antibody-drug conjugates (ADCs) are all the rage and, trying to improve on the targeting of specific antigens, proteins, receptors in the field of oncology is certainly a hot and emerging topic. Dr. Giuseppe Curigliano: So, thanks a lot. I believe really it was very challenging to try to summarize all the bispecific antibodies that are under development in multiple solid tumors. So, the first thing that I would like to highlight is the context and the mechanism of action of bispecific antibodies. Bispecific antibodies represent a groundbreaking advancement in cancer immunotherapy, because these engineered molecules have the unique ability to target and simultaneously bind to two distinct antigens. That is why we call them bispecific. So typically, one antigen is expressed on the tumor cell and the other one is expressed on the immune effectors, like T-cell or natural killer cells. So this dual targeting mechanism offers several key advantages over conventional monoclonal antibodies because you can target at the same time the tumor antigen, downregulating the pathway of proliferation, and you can activate the immune system. So the primary mechanism through which bispecific antibodies exert their therapeutic effects are: First, T-cell redirecting. I mean, many bispecific antibodies are designed to engage tumor-associated antigens like epidermal growth factor receptor, HER2, on the cancer cell and a costimulatory molecule on the surface of T-cell. A typical target antigen on T-cell is CD3. So what does it mean? That you activate the immune system, immune cells will reach the tumor bed, and you have a dual effect. One is downregulating cell proliferation, the other one is activation of the immune system. This is really important in hematological malignancies, where we have a lot of bispecifics already approved, like acute lymphoblastic leukemia or non-Hodgkin lymphoma.  The second, in fact, is the engagement of the tumor microenvironment. So, if you engage immune effector cells like NK cells or macrophages, usually the bispecific antibodies can exploit the immune system's ability to recognize and kill the immune cells, even if there is a lack of optimal antigen presentation.  And finally, the last mechanism of action, this may have a role in the future, maybe in the early cancer setting, is overcoming immune evasion. So bispecific antibodies can overcome some of the immune evasion mechanisms that we see in cancer. For example, bispecific antibodies can target immune checkpoint receptors, like PD-L1 and CTLA-4. Actually, there is a bispecific under development in breast cancer that has a dual targeting on vascular endothelial growth factor receptor and on PD-L1. So you have a dual effect at the same time. So, what is really important, as a comment, is we need to focus first on the optimal format of the bispecific, the optimal half-life, the stability, because of course even if they are very efficient in inducing a response, they may give also a lot of toxicities. So in clinical trials already, we have several bispecifics approved. In solid tumors, very few, specifically amivantamab for non-small cell lung cancer, but we have a pipeline of almost 40 to 50 bispecifics under development in multiple solid tumors, and some of them are in the context of prospective randomized trials. Dr. Hope Rugo: So this is really a fascinating area and it's really exciting to see the expansion of the different targets for bispecific antibodies. One area that has intrigued me also is that some of the bispecifics actually will target different parts of the same receptor or the same protein, but presumably those will be used as a different strategy. It's interesting because we have seen that, for example, in targeting HER2. Dr. Giuseppe Curigliano: Oh, yes, of course. You may consider some bispecifics like margetuximab, I suppose, in which you can target specifically two different epitopes of the same antigen. This is really an example of how a bispecific can potentially be more active and downregulating, let us say, a pathway, by targeting two different domains of a specific target antigen. This is an important point.  Of course, not all the bispecifics work this way, because some of the target antigen may dimerize, and so you have a family of target antigen; an example is epidermal growth factor receptor, in which you have HER1, HER2, HER3, and HER4. So some of them can inhibit the dimerization between one target antigen and the other one, in order to exert a more antiproliferative effect. But to be honest, the new generation of them are more targeting two different antigens, one on the tumor and one on the microenvironment, because according to the clinical data, this is a more efficient way to reduce proliferation and to activate the immune system. Dr. Hope Rugo: Really interesting, and I think it brings us to the next topic, which is really where bispecific antibodies have already shown success, and that is in hematologic malignancies where we have seen very interesting efficacy and these are being used in the clinic already. But the expansion of bispecific antibodies into solid tumors faces some key challenges. It's interesting because the challenges come in different shapes and forms. Tell us about some of those challenges and strategies to optimize bispecific antibody design, delivery, patient selection, and how we are going to use these agents in the right kind of clinical trials. Dr. Giuseppe Curigliano: This is really an excellent question because despite bispecific antibodies having shown a remarkable efficacy in hematological malignancies, their application in solid tumors may have some challenges. The first one is tumor heterogeneity. In hematological malignancy, you have a clear oncogene addiction. Let us say that 90% of the cells may express the same antigen. In solid tumors, it is not the same. Tumor heterogeneity is a typical characteristic of solid tumors, and you have high heterogeneity at the genetic, molecular, and phenotypic levels. So tumor cells can differ significantly from one another, even if within the same tumor. And this heterogeneity sometimes makes it difficult to identify a single target antigen that is universally expressed in an hematological malignancy. So furthermore, sometimes the antigen expressed on a tumor cell can be also present on the normal tissue. And so you may have a cross-targeting. So let's say, if you have a bispecific against epidermal growth factor receptor, this will target the tumor but will target also the skin with a lot of toxicity. The second challenge is the tumor microenvironment. The solid tumor microenvironment is really complex and often immunosuppressive. It is characterized by the presence of immunosuppressor cells like the T regulators, myeloid derived suppressor cells, and of course the extracellular matrix. All these factors hinder immune cell infiltration and also may reduce dramatically the effectiveness of bispecific antibodies. And as you know, there is also an hypoxic condition in the tumor. The other challenge is related to the poor tumor penetration. As you know also with antibody-drug conjugate, only 1 to 3% of the drug will arrive in the tumor bed. Unlike hematological malignancies where tumor cells are dispersed in the blood and easily accessible, the solid tumors have a lot of barriers, and so it means that tumor penetration can be very low. Finally, the vascularity also of the tumor can be different across solid tumors. That is why some bispecifics have a vascular endothelial growth factor receptor or vascular endothelial growth factor as a target. Of course, what do we have to do to overcome these challenges? First, we have to select the optimal antigen. So knowing very well the biology of cancer and the tumor-associated antigens can really select a subgroup of epitopes that are specifically overexpressed in cancer cells. And so we need to design bispecifics according to the tumor type. Second, optimize the antibody format. So there are numerous bispecific antibody formats. We can consider the dual variable domain immunoglobulin, we specified this in our paper. The single chain variable fragments, so FC variable fragments, and the diabodies that can enhance both binding affinity and stability. And finally, the last point, combination therapies. Because bispecific antibodies targeting immune checkpoint, we have many targeting PD-1 or PD-L1 or CTLA-4, combined eventually with other immune checkpoint inhibitors. And so you may have more immunostimulating effect. Dr. Hope Rugo: This is a fascinating field and it is certainly going to go far in the treatment of solid tumors. You know, I think there is some competition with what we have now for antibody-drug conjugates. Do you see that bispecifics will eventually become bispecific ADCs? Are we going to combine these bispecific antibodies with ADCs, with chemotherapy? What is the best combination strategy do you think looking forward? Dr. Giuseppe Curigliano: So, yes, we have a bispecific ADC. We have actually some bispecifics that are conjugated with a payload of chemotherapy. Some others are conjugated with immunoactivation agents like IL-2. One of the most effective strategies for enhancing bispecific activity is the combination therapy. So which type of combination can we do? First, bispecific antibodies plus checkpoint inhibitors. If you combine a bispecific with an immune checkpoint, like anti-PD-1, anti-PD-L1, or anti-CTLA-4, you have more activity because you have activation of T-cells, reduction of immunosuppressive effect, and of course, the capability of this bispecific to potentiate the activity of the immune checkpoint inhibitor. So, in my opinion, in a non-small cell lung cancer with an expression of PD-L1 more than 50%, if you give pembrolizumab plus a bispecific targeting PD-L1, you can really improve both response rate and median progression-free survival.  Another combination is chemotherapy plus bispecific antibodies. Combining chemotherapy with bispecific can enhance the cytotoxic effect because chemotherapy induces immunogenic cell death, and then you boost with a bispecific in order to activate the immune system. Bispecific and CAR T-cells, until now, we believe that these are in competition, but this is not correct. Because CAR T-cells are designed to deliver an activation of the immune system with the same lymphocytes engineered of the patients, with a long-term effect. So I really do not believe that bispecifics are in competition with CAR T-cells because when you have a complete remission induced by CAR T-cell, the effect of this complete remission can last for years. The activity of a bispecific is a little bit different. So there are some studies actually combining CAR T-cells with bispecifics. For example, bispecific antibodies can direct CAR T-cells in the tumor microenvironment, improving their specificity and enhancing their therapeutic effect.  And finally, monoclonal antibody plus bispecific is another next generation activity. Because if you use bispecific antibodies in combination with existing monoclonal antibodies like anti-HER2, you can potentially increase the immune response and enhance tumor cell targeting. In hematological malignancies, this has been already demonstrated and this approach has been particularly effective. Dr. Hope Rugo: That's just so fascinating, the whole idea that we have these monoclonal antibodies and now we are going to add them to bispecifics that we could maybe attach on different toxins to try and improve this, or even give them with different approaches. I suppose giving an ADC with a bispecific would sort of be similar to that idea of giving a monoclonal antibody with the bispecific. So it is certainly intriguing. We also will need to understand the toxicity and cost overall and how we are going to use these, the duration of treatment, the assessment of biomarkers. There are just so many different aspects that still need to be explored.  And then with that idea, can you look ahead five or ten years from now, and tell us how you think bispecific antibodies will shape our next generation cancer therapies, how they will be incorporated into precision oncology, and the new combinations and approaches as we move forward that will help us tailor treatment for patients both with solid tumors and hematologic malignancies? Are we going to be giving these in early-stage disease in solid tumors? So far, the studies are primarily focusing on the metastatic setting, but obviously one of the goals when we have successful treatments is to move them into the early stage setting as quickly as possible. Dr. Giuseppe Curigliano: Let us try to look ahead five years rather than ten years, to be more realistic. So, personally I believe some bispecifics can potentially replace current approaches in specifically T-cell selected population. As we gather more data from ongoing clinical trials and we adopt a deeper understanding of the tumor immuno microenvironment, of course we may have potentially new achievement. A few days ago, we heard that bispecifics in triple negative breast cancer targeting VEGF and PD-L1 demonstrated an improvement in median progression-free survival.  So, how to improve and to impact on clinical practice both in the metastatic and in the early breast cancer setting or solid tumor setting? First, personalized antigen selection. So we need to have the ability to tailor bispecific antibody therapy to the unique tumor profile of individual patients. So the more we understand the biology of cancers, the more we will be able to better target. Second, bispecific antibodies should be combined. I can see in the future a potential trial in which you combine a bispecific anti-PD-L1 and VEGF with immune checkpoint inhibitor selected also to the level of expression of PD-L1, because integration of antibody bispecific with a range of immunotherapies, and this cannot be only immune checkpoint inhibitors, but can be CAR T-cells, oncolytic viruses, also targeted therapy, will likely be a dominant theme in the coming years. This combination will be based on the specific molecular and immuno feature of the cancer of the patient.  Then we need an enhanced delivery system. This is really important because you know now we have a next generation antibody. An example are the bicyclic. So you use FC fragment that are very short, with a low molecular weight, and this short fragment can be bispecific, so can target at the same time a target antigen and improving the immune system. And so the development of this novel delivery system, including also nanoparticles or engineered viral vectors, can enhance the penetration in the tumor bed and the bioavailability of bispecific antibodies. Importantly, we need to reduce toxicity. Until now, bispecifics are very toxic. So the more we are efficient in delivering in the tumor bed, the more we will reduce the risk of toxicity. So it will be mandatory to reduce off-target effects and to minimize toxicity.  And finally, the expansion in new indication. So I really believe you raised an excellent point. We need to design studies in the neoadjuvant setting in order to better understand with multiple biopsies which is the effect on the tumor microenvironment and the tumor itself, and to generate hypotheses for potential trials or in the neoadjuvant setting or in those patients with residual disease.  So, in my opinion, as we refine design, optimize patient selection, and explore new combination, in the future we will have more opportunity to integrate bispecifics in the standard of care. Dr. Hope Rugo: I think it is particularly helpful to hear what we are going to be looking for as we move forward to try and improve efficacy and reduce toxicity. And the ability to engineer these new antibodies and to more specifically target the right proteins and immune effectors is going to be critical, of course, moving forward, as well as individualizing therapy based on a specific tumor biology.  Hearing your insights has been great, and it really has opened up a whole area of insight into the field of bispecifics, together with your excellent contribution to the ASCO Educational Book. Thank you so much for sharing your thoughts and background, as well as what we might see in the future on this podcast today. Dr. Giuseppe Curigliano: Thank you very much for the invitation and for this excellent interview. Dr. Hope Rugo: And thanks to our listeners for joining us today. You will find a link to the Ed Book article we discussed today in the transcript of this episode. It is also, of course, on the ASCO website, as well as on PubMed. Please join us again next month on By the Book for more insightful views on the key issues and innovations that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement. Follow today's speakers:       Dr. Hope Rugo  @hope.rugo  Dr. Giuseppe Curigliano @curijoey Follow ASCO on social media:       @ASCO on X (formerly Twitter)       ASCO on Bluesky      ASCO on Facebook       ASCO on LinkedIn       Disclosures:      Dr. Hope Rugo:   Honoraria: Mylan/Viatris, Chugai Pharma  Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer  Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  Dr. Giuseppe Curigliano: Leadership: European Society for Medical Oncology, European Society of Breast Cancer Specialists, ESMO Open, European Society for Medical Oncology Honoraria: Ellipses Pharma Consulting or Advisory Role: Roche/Genentech, Pfizer, Novartis, Lilly, Foundation Medicine, Bristol-Myers Squibb, Samsung, AstraZeneca, Daiichi-Sankyo, Boerigher, GSK, Seattle Genetics, Guardant Health, Veracyte, Celcuity, Hengrui Therapeutics, Menarini, Merck, Exact Sciences, Blueprint Medicines, Gilead Sciences Speakers' Bureau: Roche/Genentech, Novartis, Pfizer, Lilly, Foundation Medicine, Samsung, Daiichi Sankyo, Seagen, Menarini, Gilead Sciences, Exact Sciences Research Funding: Merck Travel, Accommodations, Expenses: Roche/Genentech, Pfizer, Daiichi Sankyo, AstraZeneca      

WFR Radio 447 How Big Is Your Tax Tumor by Tony Walker Financial

Kidney cancer management is evolving. How are experts adapting? In this installment of BackTable Tumor Board, Dr. Brandon Manley (Urologic Oncology, Moffitt Cancer Center), Dr. Raquibul Hannan (Radiation Oncology, UT Southwestern), and Dr. Rana McKay (Medical Oncology, UC San Diego) join guest host Mark Ball (Urologic Oncology, National Cancer Institute) to share their multidisciplinary perspectives on challenging, real-world kidney cancer cases.---This podcast is supported by:Ferring Pharmaceuticalshttps://ad.doubleclick.net/ddm/trackclk/N2165306.5658203BACKTABLE/B33008413.420220578;dc_trk_aid=612466359;dc_trk_cid=234162109;dc_lat=;dc_rdid=;tag_for_child_directed_treatment=;tfua=;gdpr=${GDPR};gdpr_consent=${GDPR_CONSENT_755};gpp=${GPP_STRING_755};gpp_sid=${GPP_SID};ltd=;dc_tdv=1---SYNPOSISThe conversation covers diagnostic dilemmas, navigating the treatment options of surgery, systemic therapy, and radiation, and the importance of a multidisciplinary approach. Through detailed case reviews, the panel highlights practical pearls, emerging clinical trials, and collaborative approaches that exemplify modern kidney cancer care.---TIMESTAMPS0:00 - Introduction02:20 - Case 1 (Incidental Renal Mass)16:52 - Case 2 (Bilateral Renal Masses)37:22 - Case 3 (Locally Advanced Renal Mass)56:34 - Case 4 (Symptomatic, Metastatic Disease)01:14:00 - Final Takeaways

Krebs bei jungen Menschen; Quarks Radio; KI kann Gefühle; Kommentar: Nobelpreis - ein veraltetes Ritual?; Nobelpreis Physik; Wie kann guter Umgang mit TikTok aussehen?; Wie sinnvoll sind Trigger-Warnungen?; Warum Frauen länger leben als Männer; Risiken und Nebenwirkungen von Psychotherapie; Moderation: Marlis Schaum. Von WDR 5.

Functional synapses between brain cells and cancer cells are key to the metastatic growth, according to new findings from two independent teams.

In this episode with Meagan Lindquist, you’ll discover the world of AHCC, a cultured mushroom extract with a remarkable range of health benefits. We explore its origins, patented culturing process in Japan, and what makes AHCC uniquely bioavailable compared to other mushroom supplements. Meagan shares her health journey, her experiences supporting patients, and her passion for spreading awareness about AHCC’s research-backed potential—from cancer and HPV to Lyme disease and overall immune function. The conversation highlights AHCC’s role as an immunomodulator, antioxidant, and anti-inflammatory compound, reviewing studies that demonstrate its benefits for general immune support and as complementary therapy for serious conditions, such as cancer and chronic infections. Practical topics include supplement quality, dosing, and how to find credible sources. By the end, you’ll have insights and actionable information to evaluate AHCC as part of a thoughtful, science-driven approach to immune optimization and integrative health. Meagan (Mimi) Lindquist (@mimi_themedicin) is the co-founder of The Medicin, alongside her husband Chase. Together, they provide high-quality mushroom products to the world. With her background as a clinical dental hygienist, nutrition guide, and AHCC educator, she has been helping others prevent disease for over 12 years. Now, Mimi is dedicated to sharing the benefits of Immune Intel AHCC, a mushroom product unlike any other, to as many people as possible. She hosts monthly live calls with Dr. Nathan Riley for women trying to clear HPV naturally using AHCC. In her words, it is her "life's passion to spread the word about how powerful it is." Full show notes: bengreenfieldlife.com/ahccpodcast Episode Sponsors: Organifi Shilajit Gummies: Harness the ancient power of pure Himalayan shilajit anytime you want with these convenient and tasty gummies. Get them now for 20% off at organifi.com/Ben. BlockBlueLight: BlockBlueLight BioLights are the only lights extensively tested and recommended by building biologist Brian Hoyer as truly flicker-free, ultra-low EMF, and circadian-friendly, with three modes (day, evening, night) that support natural rhythms and optimize sleep quality. Get 10% off your first order at blockbluelight.com/Ben (discount autoapplied at checkout). Fatty15: Fatty15 is on a mission to optimize your C15:0 levels and help you live healthier, longer. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/BEN and using code BEN at checkout. LVLUP Health: I trust and recommend LVLUP Health for your peptide needs as they third-party test every single batch of their peptides to ensure you’re getting exactly what you pay for and the results you’re after! Head over to bengreenfieldlife.com/lvluphealth and use code BEN15 for a special discount on their game-changing range of products. BiOptimizers Magnesium Breakthrough: The 7 essential forms of magnesium included in this full spectrum serving help you relax, unwind, and turn off your active brain after a long and stressful day so you can rest peacefully and wake up feeling refreshed, vibrant, and alert. Go to bioptimizers.com/ben and use code ben15 for 15% off any order.See omnystudio.com/listener for privacy information.

10-03-25 - New Update On Tumor Listener Gary His Wife Who Flew To See Him In Hospital - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

10-03-25 - New Update On Tumor Listener Gary His Wife Who Flew To See Him In Hospital - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Is microwave ablation only for simple liver tumors, or can it be a versatile ‘Swiss Army knife' for a wide range of complex cases? In this episode, Dr. Driss Raissi of the University of Kentucky returns to BackTable to join host Dr. Chris Beck for a deep dive into advanced and unconventional microwave ablation techniques. They cover strategies for tackling a wide range of cases, from desmoid tumors to enterocutaneous fistulas.---This podcast is supported by:Medtronic Emprinthttps://www.medtronic.com/emprint---SYNPOSISDr. Raissi shares his ‘pre-burn' technique that desiccates tissue and reduces complications like capsular burst and bleeding. He elaborates on his method for tackling large liver tumors with a single probe through overlapping ablations, needle placement techniques and his ‘lung seal technique' to prevent pneumothorax. Dr. Raissi also shares how his previous experience in the ICU promotes close communication with anesthesiologists and how he ups his ablation game through collaboration, optimizing conditions for safe and effective ablation.The episode explores a series of unique, real-world applications beyond the usual scope of IRs. Dr. Raissi walks us through his novel approach to challenging cases, including cauterization of enterocutaneous fistulas, endometriomas and desmoid tumors. He also compares using microwave or cryoablation for renal cell carcinoma, explaining thought processes based on lesion location and the need for speed and simplicity. The discussion provides an overview of ablation physics and careful techniques that expand treatment possibilities for IR patients.---TIMESTAMPS00:00 - Introduction 04:08 - Advanced Techniques for Liver Tumor Ablation06:06 - Pre-Burning Ablation and Ablating a Range of Lesions16:38 - Lung Ablation22:00 - Partnering with Anesthesia28:53 - Managing Postoperative Pain and Nerve Injuries29:42 - Treating Enterocutaneous Fistulas, Endometriomas & Desmoid Tumors38:49 - Adrenal Gland Ablation: A Case Study44:50 - Microwave vs. Cryoablation for Renal Cell Carcinoma49:06 - Preventing Pneumothorax in Lung Ablation

Guest: Danielle O'Laughlin, PA-C, MS Hosts: Danielle O'Laughlin, PA-C, MS and Jenna Wygant, APRN, CNP, DNP In this episode, Danielle O'Laughlin discusses benign breast tumor conditions and other non-cancerous growths. Listeners will gain insight into the clinical presentation, diagnostic evaluation, and management strategies for these common breast findings. Learning Objectives: Review the types of benign breast tumors and their clinical features. Differentiate between symptoms, diagnostic approaches, and treatment options for various benign breast conditions. Learn more about this series: Mayo Clinic Talks: Obstetric and Gynecologic Health | Mayo Clinic School of Continuous Professional Development Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

In this groundbreaking episode, we dive deep into MOJO Health's "Data Iceberg" concept that's revolutionizing cancer care. Many people make life-changing medical decisions using only 2 types of data - biopsy results and imaging scans. If you go to the most advanced cancer centers, you likely use 6, but there are 7 additional categories of health data hiding beneath the surface that will transform your healing strategy.What You'll Discover:- Why most healthcare operates on "tip of the iceberg" data- The 13 hidden data categories that predict treatment success- How molecular DNA profiling creates personalized treatment roadmaps- The power of circulating tumor DNA (liquid biopsies) for real-time monitoringPerfect for: Cancer patients, survivors, caregivers, healthcare advocates, and anyone who wants to transform from reactive to proactive healthcare.Remember: Data G's don't just hope their treatment is working. They know.Resources Mentioned:For our downloadable Guide to Be a Data G, please go to mojohealth.org/datagguideTo set up an appointment with Oscar Sierra, please reach out to https://www.sierracollaborativemed.com/To see National Cancer Institute's page the blood biomarkers: https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-listAnd here for information on different types of data to request: https://www.mojohealth.org/be-a-data-g-1Other Podcasts to watch:#4 A Data G's Guide to Beating Cancer w/ Julie Stevens and Oscar Sierra, L.Ac.#6 BRCA2 Data Dilemma: Lessons in Gene Expression#8 How Genomic Testing Can Transform Your Cancer JourneyWhat tests do you need your doctor to order? Biopsy, Imaging, Circulating Tumor DNA, and Molecular DNA of the Tumor.Basically everything else you can order on your own through Direct Patient Labs: https://www.mojohealth.org/direct-labs-mojo-panelsConnect with Julie Stevens and the MOJO Movement: Instagram: https://instagram.com/mojohealthorg TikTok: https://tiktok.com/@julie.stevens97YouTube: https://www.youtube.com/@mojohealth Facebook: https://facebook.com/mojohealthorg Website: https://www.mojohealth.org/DISCLAIMER: The views, thoughts, and opinions expressed on this podcast are the speaker's own and do not represent the views, thoughts, and opinions of MOJO Health Cooperative LLC, a Georgia Limited Liability Company, its respective officers, directors, employees, agents, or representatives. This podcast is presented by MOJO Health Cooperative, and cannot be copied or rebroadcast without consent. The material and information presented here is for general information purposes only, and not intended to supplant the expert advice and/or consultation of a medical doctor and/or a licensed physician, and/or an attorney. In short, this podcast is not intended to replace professional medical advice, nor legal advice. The "MOJO Health" name and all forms and abbreviations are the property of its owner and its use does not imply endorsement of or opposition to any specific organization, product, or service. Again, none of the content of this podcast should be considered legal advice, nor medical advice. As always, consult a lawyer and/or a licensed physician in lieu of relying upon the advice of any of the participants of this podcast. The host(s) of this podcast are not licensed lawyers, physicians, doctors of osteopath, nor medical doctors in any jurisdiction anywhere. The host(s) of this podcast do not practice medicine and do NOT profess to be able to do any of the following: (1) diagnose, heal, treat, prevent, prescribe for, or removing any physical, mental, or emotional ailment or supposed ailment of an individual; (2) engage in the end of human pregnancy; (3) treat human ailments; nor (4) perform acupuncture. MOJO Health Cooperative LLC is not responsible for any losses, damages, or liabilities that may arise from the use of this podcast.

In this episode we catch up with Zack Round. Zack is known as the Tumor Warrior and does a lot for others who suffer from brain tumors like Zack had. We get to catch up and talk about his re-branding in this episode. Support for the Segment Podcast are brought to you by:THE SEGMENT / DISCOUNT CODES / SUPPORTERSYT Industrieshttps://us.yt-industries.com/Etnies MTB Shoes: Promocode TheSegment30https://etnies.com/collections/bike-mtb Versus Tires: www.versustires.comTASCO MTB Apparel 15% offhttps://tasco-mtb-2.kckb.st/3bb12b05Promo Code: SEGMENT24 Spy Optic: https://www.spyoptic.com/Promo code SEGMENT20  20% off your purchaseKapu CoffeePurchase "The Sender" here: https://kapucoffee.com/pages/segment25% of the proceeds help the charity "Making Spirits Bright" which helps get kids outside and on bikes.https://msbfoundation.org/Kali Protectiveshttps://kaliprotectives.com/collections/full-face/products/dh-invader?variant=41188142481502Promo Code Segment25Mother Earth Brew Company: https://www.motherearthbrewco.com/PelliBikeCare: https://www.pellibikecare.com/Strong Coffee: 15% off https://strongcoffeecompany.com/?ref=Segment30Or use promo code SEGMENT15 at checkout. To become a Podcaster for Free try this link:   https://streamyard.com/pal/c/4674191405613056PHAT Lids: https://www.phatlids.com/Use promo code SEGMENT to get 10% off at checkout. SALTSTICK https://aletenutrition.com/pages/saltstick Use promo code SEGMENT20 to get 20% off

The only way to follow up last week's milestone is with the rarest of the rare medical cases. Fun. — Support and sponsor this show! Venmo Tip Jar: @wellthatsinteresting Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@wellthatsinterestingpod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Bluesky: @wtipod Threads: @wellthatsinterestingpod Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@wti_pod⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Listen on YouTube!! Oh, BTW. You're interesting. Email YOUR facts, stories, experiences... Nothing is too big or too small. I'll read it on the show: wellthatsinterestingpod@gmail.com WTI is a part of the Airwave Media podcast network! Visit AirwaveMedia.com to listen and subscribe to other incredible shows. Want to advertise your glorious product on WTI? Email me: wellthatsinterestingpod@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textDr Kate Lund is a psychologist, TEDx speaker, and podcast host of The Optimized Mind, and she spends her days helping people turn those "what now?" Moments into genuine resilience.. Her work centers on translating over 20 years of research into simple, science-backed habits that real humans can use during in their hardest of times, whether they're navigating parenthood, setbacks, or that feeling of life falling apart.Dr Kate talks about her early childhood with hydrocephalus, (she explains what that is!!) and subsequent tumor diagnosis, and how that set her apart as different than her peers and at the same time fostered a sense of resilience and possibility beyond the challenges. As a best selling author, she has seen firsthand how messy, imperfect resilience can change someone's story. Her book, ‘Step Away: The Keys to Resilient Parenting', is out in October 2025. Book: https://a.co/d/4CaffaCSite: Www.katelundspeaks.com TedX: https://www.youtube.com/watch?v=-p6YcTsWySU&t=14sThe Dom Sub Living BDSM and Kink PodcastCurious about Dominance & submission? Real stories, real fun, really kinky.Listen on: Apple Podcasts SpotifySupport the show

In this episode of Blood Cancer Talks, hosts Eddie, Ashwin, and Raj welcome two distinguished experts to explore the cutting-edge field of circulating tumor DNA (ctDNA) in B-cell lymphomas. Dr. David Russler-Germain, a lymphoma clinician from Siteman Cancer Centre at Washington University in St. Louis, returns as a familiar voice to the podcast audience. Joining him is Dr. Ash Alizadeh, the Moghadam Family Professor of Medicine, Oncology, and Hematology at Stanford University and leader of the Cancer Genomics Program at Stanford Cancer Institute. Dr. Alizadeh has been instrumental in advancing our understanding of lymphomagenesis and lymphoma genetics over the past two decades, pioneering multiple ctDNA techniques that are revolutionizing cancer care. Together, they discuss the transformative potential of ctDNA technology in B-cell lymphomas, particularly DLBCL, covering everything from the technical evolution of biomarker detection to groundbreaking clinical data that may reshape how we monitor and treat these aggressive cancers. Key Discussion Topics1. Genetic Heterogeneity in B-Cell LymphomasComplex genetic landscape of DLBCLImplications for treatment strategiesNeed for personalized approaches 2. Clinical Need for ctDNA in LymphomaWhy ctDNA is needed in aggressive lymphomas:Curative vs. non-curative treatment settingsLimitations of current PET imagingAdditional prognostic information beyond imagingRisk stratification capabilitiesPotential to avoid overtreatmentTherapy adaptation opportunities 3. Challenges in Lymphoma MRD AssessmentWhy lymphoma MRD is more complex than other hematologic malignancies:Differences from acute leukemias, CLL, and myelomaTechnical challenges specific to lymphoid tumorsLower circulating tumor burden compared to liquid tumors 4. ClonoSEQ TechnologyMechanism: Immunoglobulin sequencing approachAdvantages: Established platform with regulatory approvalDisadvantages: Limited sensitivity in peripheral blood, requires adequate tumor sample 5. CAPP-Seq TechnologyFull Name: Cancer Personalized Profiling by Deep SequencingInnovation: Developed ~10 years ago by Dr. Alizadeh's groupMechanism: Targeted sequencing of cancer-specific mutationsAdvantages: High sensitivity, personalized approach 6. PhasED-Seq TechnologyEvolution: Next-generation advancement of CAPP-SeqKey Improvements: Enhanced sensitivity and specificityTechnical Advances: Phased variant detection Clinical Data Highlights1. Remission Assessment by ctDNA in LBCL on 5 prospective studies of frontline anthracycline-based chemo-immunotherapy: https://pubmed.ncbi.nlm.nih.gov/40802906/2. Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from HOVON-902 clinical trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.70003. Korean data on prognostic utility of ctDNA: https://ashpublications.org/blood/article/142/Supplement%201/69/501573 

He let it go for 16 years!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Stupid News 9-23-2025 8am …Dumbest Lawsuit of the Year …He somehow got His Head Stuck inside a Traffic Light …It is a Tumor

Fr. Eric Nielsen joins Patrick to discuss Miracles: Padre Pio Who was Padre Pio and what miracles did he do? (14:03) Why do some people get miracles and others don’t? (17:19) Juliette - My father was in a bad accident. He is on a ventilator. Tried to remove it. Did not succeed. 84 years old. At what point is it too much. Miracle he survived. I feel like there have been some answered prayers. Is that a miracle in itself that he was able to communicate his wishes? (22:05) Break 1 (23:45) Helen - When my daughter was 3, my daughter had a brain tumor. She had tumor removed. Came back. Went through surgery again, I prayed and asked that she not suffer if she was going to be taken. Tumor disappeared and now she's 39 years old. She's my miracle baby. Does God allow bargaining? Dan - I worked as a hospice chaplain, and one of the greatest pieces of advice...sometimes we just need to get out of God's way and let God do what he needs to do. The miracle of bringing a soul to heaven is the ultimate miracle. (32:53) Brenda - My cousin heard mass by Padre Pio. Was part of my conversion to Catholicism. (37:10) Break 2 Barbara - Miracle when I was baptized. I was instantly delivered from smoking cigarettes. 45-year smoker. (41:59) Eileen - The priest who got me into my faith was leading a colorful life. Padre Pio told him he would become a priest one day. Love the story that he told him he would become a priest. Father shares an email about how can we pray when God doesn’t answer our prayer? (46:13) Brenda - Years after my mom passed, I was thinking about her and praying and walked to the living room and noticed a little star out of nowhere. I think it was a sign and miracle that she was there. Had this happen several other times. Miracle think it was the Lord saying 'I have them.'